An Israeli pharmaceutical company says it will have a "complete cure for cancer" next year.
The company is Biotechnology of Accelerated Evolution (AEBi), and based on the statements of its board chairman, Dan Aridor, the treatment that is working on sounds other than revolutionary.
"Our cancer treatment will be effective from the first day, it will last for a few weeks and will not have minimal side effects at a much lower cost than the rest of the other treatments on the market," said Aridor The Jerusalem Post. "Our solution will be generic and personal."
Done with The Jerusalem Post, AEBi cancer healing is called MuTaTo, which means "multipurpose toxin". It attacks cancer cells with various peptides, compounds that form amino acid chains, at the same time, and this multiple attack is key to the efficacy of the treatment. says the company.
"We make sure that the treatment will not be affected by mutations; the cancer cells can mutate so that the cells fall targeted receptors," said CEO of AEBi, Ilan Morad Publication. "The probability of having multiple mutations that modify all the specific receivers diminishes dramatically with the number of targets used".
"Instead of attacking receivers one by one, we attack the receivers three at a time," he continued. "Not even cancer can mutate three receptors at the same time."
State of the cure
Morad's claims to the Publication that AEBi has used its cancer treatment to inhibit the growth of human cancer cells in mice without affecting the healthy cells of animals. The company has also conducted several trials in vitro and will soon begin clinical trials, according to Morad. These could be involved in a few years, CEO of AEBi said, after which the treatment could be available in specific cases.
This is a lot of claims, but the Publication The article does not mention the existence of any expert-reviewed investigations that may back up.